-
Pradaxa Approval – Great News!
The new oral anticoagulant Pradaxa® (Dabigatran) was approved by the FDA on October 20th, 2010 [ref 1,2]. As of Feb 3rd, 2012, Pradaxa® is only FDA approved for use in patients with atrial fibrillation. It is not approved yet for patients with DVT and PE.
A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center
Clot Connect 